Opinion
Video
Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
Author(s):
Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.
Video content above is prompted by the following:
- Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Related Videos
Related Content
December 26th 2024
